Summary The role of cholecystokinin in dietary fat-promoted pancreatic carcinogenesis was investigated in azaserine-treated rats, using lorglumide, a highly specific cholecystokinin-receptor antagonist. The animals were killed 8 months after the start of treatment.
Dietary fat has been implicated in the aetiology of various human cancers, including pancreatic cancer. Epidemiology has revealed a direct association between total fat consumption and mortality of pancreatic cancer (Gordis & Gold, 1984; Lin & Kessler, 1981; MacMahon, 1982; Wynder et al., 1973) . Studies with azaserine-treated rats and with N-nitrosobis(2-oxopropyl)amine (BOP)-treated hamsters have demonstrated that a diet high in unsaturated fat (maize oil) promotes the development of pancreatic tumours (Roebuck et al., 1981a (Roebuck et al., , 1981b Longnecker et al., 1986; Woutersen et al., 1986 Woutersen et al., , 1989 Birt et al., 1981 ). An increase in intraduodenal cholecystokinin (CCK) release is one of the postulated mechanisms by which a high-fat diet may be linked to a high risk for pancreatic cancer. The cells producing the gut hormone CCK are located in the small intestine and release CCK into the circulation upon ingestion of food. CCK is believed to be the most important hormonal regulator of pancreatic enzyme secretion, and it is assumed that those nutrients that stimulate pancreatic enzyme secretion do so by stimulating CCK release. Douglas et al. (1988) have demonstrated that unsaturated fat as well as protein administered intragastrically to rats causes a rapid and significant rise in plasma CCK exceeding the threshold for pancreatic stimulation. This result suggests that CCK release induced by fat and protein may play a role in the postprandial stimulation of the pancreas in rats. In human volunteers ingestion of fat also causes a rise in plasma CCK levels, especially with an unsaturated fat such as maize oil (Beardshall et al., 1989) .
Moreover, it has been demonstrated that lorglumide, a highly specific CCK receptor antagonist (Makovec et al., 1985 (Makovec et al., , 1987 , inhibits the promoting effect of CCK on pancreatic growth (Douglas et al., 1989c (Douglas et al., , 1990 and on the development of putative preneoplastic acinar lesions induced in rat pancreas by azaserine (Douglas et al., 1989a,c) . Roebuck et al. (1987) , however, did not find plasma CCK increments in rats maintained on a diet high in unsaturated fat, which was due to an inadequate time of blood sampling in combination with ad libitum feeding. We have demonstrated that plasma CCK concentrations increase almost instantly after ingestion of food and return to basal levels thereafter (Douglas et al., 1988 (Douglas et al., 1988) , but has no influence on pancreatic carcinogenesis (Roebuck et al., 198 1a) .
Chemicals
Azaserine was purchased from the Calbiochem-Behring Corp., La Jolla, CA, USA. Cholecystokinin-octapeptide 5 and 6 were given the HF diet on three consecutive days per week. On these days the animals in group 6 were treated with lorglumide (12 mg kg-' body wt), while the animals in group 5 were injected with saline. The other 4 days of the week these animals were maintained on the LF diet. Lorglumide was dissolved in distilled water to a concentration of 0.4% and adjusted to pH 9 with 0.1 M NaOH and subsequently administered to the animals 30 min before injection of CCK and 30 min before the animals received their feed. Drinking water was available ad libitum. The dose of CCK used was based on plasma concentration-time curves for CCK obtained from a previously described 2-week study in rats and hamsters (Douglas et al., 1989b) . Subcutaneous injection of 2.5 lg kg-' body wt CCK, dissolved in 16% hydrolysed gelatin, resulted in plasma CCK levels that were only slightly supraphysiological and comparable with those seen after dietary administration of maize oil (Douglas et al., 1988) .
Monitoring
Body weights were recorded weekly during the first 2 weeks, every 2 weeks for 16 weeks thereafter and monthly for the rest of the experimental period. The general condition and behaviour of the animals were checked daily. A total of 31 animals, involving all groups, died before terminal autopsy. The rats that died after 350 effective days (n = 4) in the study have been included in the results. Twenty-seven rats (11%), were excluded from the results because they died or were killed in extremis before day 350 of the study. Six of these animals died or were killed owing to a bad condition caused by the repeated injections (n = 3) or the malocclusion syndrome and subsequent anorexia (n = 3). Five animals died presumably of renal failure, one rat of a bone tumour and another one of a squamous cell carcinoma of the Zymbal's gland. No cause of death could be established for 14 of the animals because no autopsy was performed due to early death (before day 85; n = 11) or to cannibalism (n = 3).
Analyses
Terminal autopsy was 371 days after the first injection of azaserine. The animals were anaesthetised with ether, exsanguinated by cannulating the abdominal aorta, and examined for gross pathological changes. The entire pancreas, liver and all gross lesions were excised. The pancreas and liver of each animal were weighed. All excised organs and all gross abnormalities suspected of being tumours were fixed in 10% buffered formalin. The entire pancreata were processed for microscopy by conventional methods, step-sectioned at 5 tim, stained with haematoxylin and eosin (H&E) and examined by light microscopy. All pancreatic lesions were identified and classified according to the criteria of Longnecker (1983) and Rao et al. (1982 Quantitative determination of the number of AACN per cm3 of pancreas was performed by using a grid inside the ocular as described (Woutersen et al., 1986; Scherer, 1981) . The calculated volumetric data were evaluated by analysis of variance. To minimise the SEM some mathematical transformations were performed. The total number of observed AACN per cm2, the mean transection area and the percentage of pancreas area occupied by focus tissue were logarithmically transformed before statistical evaluation. The calculated total number of AACN per cm3 was prepared for statistical evaluation by taking the square root. The mean diameters of AACN were not mathematically transformed. The number of pancreatic lesions was evaluated by a generalised linear regression model (error is Poisson, link function is log). The incidence and severity of pancreatic neoplasms were evaluated by a loglinear model followed by chi-square tests for goodness of fit.
Results
Body and organ weights Body weights remained similar for all groups. Both absolute and relative liver weights of all treated animals were comparable with those of controls. The pancreata of animals treated with CCK increased significantly in weight as compared with controls (P<0.01).
Microscopy Animals of the LF + lorglumide group and those of the HF group irrespective of lorglumide treatment, showed no differences in number and size of acidophilic AACN from controls on a LF diet (Table II) (Table IV) . In this group 38% of the rats developed a carcinoma versus 25% in the controls. This increase is reflected in an increased incidence (P<0.05) of animals with a microcarcinoma in the CCK-treated group. In the group treated with lorglumide prior to CCK, the inci- 14 tAll animals were fed for 4 h a day; ttLF, low fat; HF, high fat. Statistics: regression analysis (error is Poisson, link function is log); *P < 0.05; *P < 0.01; ***P < 0.001. aSignificantly different from the LF group; bTreatment with CCK caused an increase in number of microcarcinomas as compared to animals kept on a LF diet and not treated with CCK; cTreatment with Lorglumide caused a reduction in number of microcarcinomas as compared to animals not treated with Lorglumide; dA HF diet caused an increase in number ofcarcinomas as compared to animals kept on a LF diet for 7 days/week; eTreatment with CCK caused an increase in total number of carcinomas as compared to animals not treated with CCK. dence of pancreatic tumours was similar to that in controls. The group maintained on a HF diet and pre-treated with lorglumide showed a higher incidence (P < 0.05) of adenocarcinomas than controls. Since lorglumide alone did not result in a rise in incidence, the latter effect is considered to be attributable to the HF diet.
Discussion
The present study was conducted to investigate whether dietary fat-promoted pancreatic carcinogenesis in rats is mediated via an increased duodenal release of CCK. It has been demonstrated that lorglumide, a specific CCK-receptor antagonist, remains in its active form for about 4 to 6 h (Makovec et al., 1985) . To be able to modulate the CCK release induced by the ingestion of food we chose a dietary regimen consisting of one 4-h meal per day. To establish whether the enhancing effect of a HF diet on pancreatic carcinogenesis is indeed mediated via CCK, we injected lorglumide 30min before the animals received their respective diets to occupy the CCK receptors before CCK is released from the intestines. A disadvantage of the 4-h meal regimen used was a significant decrease in body weight gain as compared to a parallel study with azaserine-treated rats fed ad libitum (average body weight in the present study after 12 months was 400g versus 467 g in the parallel study). The decrease in body weight gain might be a confounding factor in the present study, since it is well known that an energyrestricted diet (10%) has a significant inhibitory effect on azaserine-induced pancreatic carcinogenesis in rats (Roebuck et al., 1981a) . Indeed, the tumour incidences in the present study appeared to be consistently lower than in the parallel study in which the animals were fed ad libitum.
The present results obtained with CCK are in agreement with those of previous studies (Douglas et al., 1989a; 1989c; . CCK administration enhances pancreatic growth as well as pancreatic carcinogenesis in azaserine-treated rats in spite of the restricted feeding regimen. Also of great interest is the observation that, whereas CCK enhances growth of acidophilic AACN, it inhibits the growth of basophilic foci. This effect of CCK is slightly inhibited by lorglumide. In a previous study we have observed the same phenomenon with the synthetic trypsin inhibitor Camostate (Douglas et al., 1989c) . These results support our conclusion that, besides acidophilic foci, also basophilic foci may be responsive to modulators of carcinogenesis and may play a role in the development of pancreatic cancer in azaserine-treated rats (Woutersen et al., 1986 . It is, therefore, of paramount importance not to neglect these putative preneoplastic lesions in studies of pancreatic carcinogenesis. Moreover, the significance of these observations needs further elucidation. Even under the circumstances of a single 4-h meal the HF diet enhances the development of pancreatic acinar adenocarcinomas, albeit less pronounced than in a previous study in which the rats were fed ad libitum (Woutersen et al., 1989) . Lorglumide did not influence the promoting effects of the HF diet on pancreatic carcinogenesis. This observation is not in agreement with that of Smith et al. (1990) , who reported that L 364,718, a potent CCK-receptor antagonist, decreased the volume and weight of a xenografted human pancreatic tumour cell line in athymic mice. Moreover, they also found a reduction in dietary fat-promoted growth of these xenografts by L 364,718. These apparently contradictory findings are most probably due to differences in tumour types induced by azaserine in rats (almost exclusively acinar adenocarcinomas) and those occurring in man (duct cell adenocarcinomas). Syrian golden hamsters treated with N-nitrosobis (2-oxopropyl)amine (BOP) develop ductular tumours which resemble those occurring in man. In the BOP-hamster model CCK has been found to have no effect or an inhibitory effect on pancreatic carcinogenesis (Pour et al., 1988; Meijers et al., 1990 ).
In the present study, CCK enhanced multiplicity and incidence of pancreatic tumours. The HF diet also promoted development of pancreatic tumours, but in a less pronounced manner. Lorglumide largely inhibited the CCK effect on pancreatic tumour development, but did not influence the effect of the HF diet. In fact, the number and incidence of adenocarcinomas was highest in the HF + lorglumide group. The latter observation may indicate a possible unknown interaction between HF and lorglumide. However, the lack of statistical evidence for such an interaction and the slight inhibitory effect observed with lorglumide alone, suggest that the promoting effect of HF + lorglumide is attributable to HF. The number of rats bearing a microcarcinoma was significantly higher in animals treated with CCK than in the other groups. Pre-treatment with lorglumide completely inhibited this effect. Moreover, CCK enhanced pancreatic weight, whereas the HF diet did not. These results indicate that both CCK and a HF diet enhance pancreatic carcinogenesis in azaserine-treated rats. The mechanism of these two promoters of pancreatic carcinogenesis, however, seems to be different. Lorglumide largely inhibited the enhancing effect of CCK, but not of dietary fat, indicating that it is unlikely that the promoting effect of dietary unsaturated fat on pancreatic carcinogenesis is mediated via CCK. The mechanism by which dietary (un)saturated fat promotes carcinogenesis is still largely unknown. Several mechanisms have been postulated by which a diet high in (un)saturated fat may be linked to a high risk for some cancers (Karmali, 1988) . A hypothetical explanation for dietary fat-promoted tumour growth involves the acceleration of linoleic acidderived arachidonic acid metabolism resulting in enhanced production of eicosanoids such as prostaglandins, thromboxanes and leukotrienes (Karmali, 1983) . Investigations are currently in progress to find out whether prostaglandins play a role in dietary fat-promoted pancreatic carcinogenesis using both the azaserine-rat and the BOP-hamster model.
